KENILWORTH, N.J., August 15, 2018 /3BL Media/ -- The Merck Foundation (the Foundation) is supporting two new programs to improve the health and wellbeing of vulnerable individuals living with Alzheimer’s disease and their caregivers. With a focus on underserved rural and urban populations in New England and Minnesota, these programs are part of the Foundation’s $5 million effort to reduce disparities in health care for underserved communities affected by Alzheimer’s.
CECP looks back at the corporate response to Charlottesville
Today marks one year since Merck CEO Ken Frazier announced his resignation from the President's American Manufacturing Council in response to what he and his company felt was a failure to appropriately denounce "expressions of hatred, bigotry and group supremacy" on the part of the federal government.
KENILWORTH, N.J., July 20, 2018 /3BL Media/ -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, has a long history of responsible pricing. In 2017, Merck issued its second annual Pricing Action Transparency Report, which showed that net prices across Merck’s U.S. product portfolio declined by 1.9 percent. We believe that further changes are still necessary to help reduce patient out-of-pocket costs. To demonstrate our commitment to achieving this goal, we are making the following announcement:
by Dr. Mary-Ann Etiebet, Executive Director of Merck for Mothers
Five years ago, Saving Mothers, Giving Life (SMGL) – a major public-private partnership – set the ambitious goal of reducing maternal mortality by half in target districts in Uganda and Zambia, and later Nigeria.
by Betsy McCallon, Chief Executive Officer, White Ribbon Alliance
Since our beginnings nearly 20 years ago, White Ribbon Alliance has brought diverse partners together to advance reproductive and maternal health and rights for women and girls. It’s always exciting to witness community, national and global partners bring their unique talents and resources together and realize a shared goal. The recently launched What Women Want campaign is especially motivating given its potential to transform accountability for reproductive and maternal health at the global and national levels.
KENILWORTH, N.J., June 27, 2018 /3BL Media/ – Merck (NYSE: MRK), known as MSD outside the United States and Canada, through its Merck for Mothers initiative announced study results on an investigational heat-stable formulation of carbetocin for the prevention of excessive bleeding after childbirth, also known as postpartum haemorrhage (PPH).
by Dr. Neel Shah, Assistant Professor at Harvard Medical School
As an obstetrician, my job is to focus on moms and babies. But one of my favorite parts of childbirth is the look on a new dad’s face at the precise moment he sees his baby for the first time. The physical connection between moms and babies begins sooner and more gradually than it does for dads. Moms feel their babies growing and wriggling months before they get to actually see them. For dads, the first physical connection is visual. Fatherhood goes from being abstract to very real in an instant. And that look is everything.
At Merck for Mothers, we believe that actionable research is essential for taking on maternal mortality. On behalf of our team and many partners, we are pleased to share Evidence for Impact, our first Research Compendium. The publications included in this compendium advance our collective understanding of the problem of maternal mortality, inform the design and implementation of programs aiming to improve women’s health, and strengthen the global health community of practice to save women’s lives.
Merck for Mothers lead Dr. Naveen Rao has announced his intent to retire on July 1. Dr. Rao has led Merck for Mothers since its inception, and was responsible for leveraging Merck's scientific and business expertise to accelerate the program's progress. Dr. Mary-Ann Etiebet, currently the executive director, will succeed Dr. Rao.